BRAF and cutaneous mastocytosis: •By in-depth mass-spectrometry-based proteomic analysis of 1,160 proteins in a subset of metastatic CM patients receiving BRAF- and MEK- inhibitors, we discovered alterations in plasma proteins involved in cell adhesion-, neutrophil degranulation-, and proteolysis- during BRAFi and MEKi treatment.